Siemens Denied Patent Rehearing In Enzo DNA Spat

Law360, New York (May 17, 2010, 6:41 PM EDT) -- Siemens Healthcare Diagnostics has lost its bid for a rehearing of the U.S. Board of Patent Appeals and Interferences' decision to award Enzo Biochem Inc. priority to an invention for nucleic acid signal amplification related to branched DNA diagnostic systems.

The denial, announced Monday by Enzo, finalizes the board's previous ruling and will give Enzo a full 17-year patent for the invention. Siemens, however, can appeal the ruling to federal court.

"This technology is the basis for a number of significant products in clinical diagnostics and...
To view the full article, register now.